When two common chronic conditions converge — type 2 diabetes and fatty liver disease — clinicians face a puzzle: which biomarkers actually predict who will develop dangerous arterial disease? The answer has real implications for how these patients are monitored and treated, and new data suggest the oldest tools may still be the sharpest.

This cross-sectional study enrolled 46 adults carrying diagnoses of both type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), evaluating their risk of atherosclerotic cardiovascular disease (ASCVD) — defined broadly to include carotid atheromatosis, stroke, peripheral arterial disease, and ischemic heart disease confirmed by imaging. Multivariable regression and ROC curve analyses were applied across a variable set that included traditional cardiometabolic risk factors, hepatic fibrosis indices (notably the FIB-4 score), and current antidiabetic medication classes such as SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. Among all tested predictors, hemoglobin A1c demonstrated the strongest discriminative performance, achieving an area under the curve of 0.77, while hepatic fibrosis markers contributed comparatively little independent predictive value after adjustment. Age showed exploratory associations that weakened in fully adjusted models.

The finding carries a degree of irony: despite growing enthusiasm for sophisticated liver fibrosis indices and newer glucose-lowering drug classes as cardiovascular risk modifiers, glycemic control — measured by a four-decade-old biomarker — retained the clearest signal. This aligns with established epidemiology linking chronic hyperglycemia to endothelial dysfunction and accelerated atherogenesis, but also reflects an important limitation. With only 46 participants, this study is substantially underpowered to detect effects of smaller magnitude, and the cross-sectional design precludes any causal inference. MASLD heterogeneity is also wide — fibrosis staging by non-invasive indices like FIB-4 carries notable imprecision, potentially masking a genuine hepatic contribution. For a patient population at genuinely elevated cardiovascular risk, these results are hypothesis-generating rather than practice-changing, warranting replication in larger longitudinal cohorts.